Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1

Interventions

E 7107 2Carboplatin 2palbociclib 1gedatolisib 1eniluracil 1dabrafenib 1abarelix 1Topotecan 1Standard of Care 1Radionuclide Imaging 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Positron-Emission Tomography 1Passive Cutaneous Anaphylaxis 1Paclitaxel 1NUC-1031 1Morphine 1Methadone 1Maltose 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1KB004 1Injections 1Infusions, Parenteral 1Hyperthermic Intraperitoneal Chemotherapy 1Hydromorphone 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasms × KB004 × Clear all
NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡